Drug Development

Articles

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Alternative materials, as well as supply-chain planning, are essential to ensure a reliable supply for parenteral drug packaging.

Setting a Clear Strategy for Primary Packaging

Consistency, robustness, and understanding of the API and controlled-release excipients are essential for successful drug dosing.

On Time Delivery: Challenges of Controlled-Release Formulations

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Getting a Nose for Vaccines

Sunday Ndiana-Abasi is an intern pharmacist at the Department of Pharmaceutical Technology and Raw Materials Development in the National Institute for Pharmaceutical Research and Development in Nigeria.

Marlene Ekpo is a youth corp pharmacist and research assistant at the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development, and a postgraduate student at the School of International Education, Southern Medical University, Guangzhou, Guangdong, China.

Martins O. Emeje, martinsemeje@yahoo.com, is a professor at the Department of Pharmaceutical Technology and Raw Materials Development and director of the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development.

The potential for okra gum as a polymer candidate for new oral drug formulations was evaluated.

Evaluating Okra Gum in a Floating Tablet Formulation as a Novel Drug Delivery System

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Will FDA’s approval of Semglee create a surge in the development of interchangeable biosimilars?

Biosimilars Move to Center Stage

Deanna Mudie, PhD, is principal scientist, Lonza, Bend, OR, USA.

The pH effect encountered with oral oncology medication can be overcome with amorphous solid dispersions.

Enhanced Bioavailability of Acalabrutinib ASD Tablets In-Vivo

Thomas A. Little, PhD, is president, Thomas A. Little Consulting and BioAssay Sciences, 12401 North Wildflower Lane, Highland, Utah 84003, USA, drlittle@dr-tom.com.

It is important to use correct organization and appropriate methods for demonstrating biosimilar comparability to support regulatory filings.

Determining Comparability of Biosimilars Through Statistical Approaches

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension. 

FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib

BioMed X has partnered with Janssen to start two new research programs for autoimmune diseases and drug delivery.

Formulation and Drug Delivery